Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Share-based Compensation (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Share-based Compensation for 6 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 29.99% to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.7 million through Dec 2025, down 24.1% year-over-year, with the annual reading at $12.7 million for FY2025, 24.1% down from the prior year.
  • Share-based Compensation for Q4 2025 was $2.7 million at Caribou Biosciences, down from $2.9 million in the prior quarter.
  • The five-year high for Share-based Compensation was $4.7 million in Q2 2024, with the low at $343000.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $2.9 million, with a median of $3.1 million recorded in 2022.
  • The sharpest move saw Share-based Compensation soared 781.63% in 2022, then plummeted 33.96% in 2025.
  • Over 5 years, Share-based Compensation stood at $1.6 million in 2021, then soared by 96.51% to $3.1 million in 2022, then rose by 14.67% to $3.6 million in 2023, then increased by 9.98% to $3.9 million in 2024, then fell by 29.99% to $2.7 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $2.7 million, $2.9 million, and $3.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.